Cost-effectiveness analysis of a strategy to delay progression to dialysis and death among chronic kidney disease patients in Lima, Peru

Table 2 Treatment cost for each stage and alternative

	Stage 1		Stage 2		Stage 3a		Stage 3b		Stage 4
	Diabetic patient (D)	Non-diabetic patient (ND)	D	ND	D	ND	D	ND	D	ND
Cohort distribution
Proportion of diabetic patients within stage (%)	51	49	42	58	29	71	24	76	22	78
Number of diabetic patients within stage (n)	1833	1781	2109	2890	2407	6026	536	1671	245	856
Proportion of patients in each stage^a (%)	18		25		41		11		5
Treatment cost intervention (USD)^b
Outpatient visits	315	315	315	315	340	340	439	370	1018	840
Laboratory tests	38	34	38	34	69	62	270	197	344	297
Drugs	47	43	47	43	47	43	118	84	335	280
Hospital overhead	20	20	20	20	20	20	40	40	40	40
Total	420	412	420	412	476	464	867	691	1736	1456
Annual cost per patient for each stage^a	416		415		468		734		1519
Annual cost per patient^c	531
Treatment cost standard of care (USD)^b
Outpatient visits	15		15		15		30		30
Laboratory test	28		28		28		28		28
Total	43		43		43		58		58
Annual cost per patient^c	45

ISSN: 1478-7547